Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Dot1L Polyclonal Antibody
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
PA5-78603
产品规格
宿主/亚型
Rabbit
/ IgG
分类
Polyclonal
类型
Antibody
抗原
Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human DOT1L. The exact sequence is proprietary.
偶联物
形式
Liquid
浓度
2 mg/mL
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
RRID
产品详细信息
Positive Control: H1299
Predicted Reactivity: Mouse (93%), Rat (93%)
Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
靶标信息
DOT1-like histone lysine methyltransferase (DOT1L) is a gene located on chromosome 19q13.12, encoding an enzyme responsible for methylating lysine 79 on histone H3, a critical modification influencing chromatin structure and gene expression. Unlike most histone methyltransferases, DOT1L does not contain a SET domain and uniquely catalyzes H3K79 methylation, which plays pivotal roles in the regulation of transcription and maintenance of genomic stability. Expression of DOT1L is vital for various biological processes, including cell cycle progression, development, and differentiation, particularly in hematopoietic cells. Aberrations in DOT1L activity have been associated with mixed-lineage leukemia (MLL), where DOT1L-mediated H3K79 methylation contributes to leukemogenesis by influencing gene expression related to proliferation and survival. Due to its involvement in cancer progression, DOT1L is being investigated as a therapeutic target, with inhibitors developed to specifically modulate its enzymatic activity, offering potential for treating MLL and other malignancies.
⚠WARNING: This product can expose you to chemicals including mercury, which is known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
